{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:13:44Z","timestamp":1791994424331,"version":"4.4.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Minneamrita"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Minnelide is a water-soluble prodrug of triptolide. Triptolide is an anticancer agent that targets cancer resistance through several mechanisms. Minnelide was evaluated in a phase I study in patients with advanced GI carcinomas to establish the safety, pharmacodynamic, antitumor activity, and recommended phase II dose (RP2D).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods<\/jats:title>\n                  <jats:p>Patients with refractory GI carcinoma and with measurable disease on CT scan were eligible. The study used a 3\u2005+\u20053 dose-escalation scheme. Due to neutropenia toxicity, 2 dosing schedules were evaluated to determine the RP2D for future studies. Response was assessed using RECIST 1.1 and Choi criteria. Minnelide and triptolide PK were evaluated. Patients who completed the first 28-day treatment cycle without DLTs continued treatment until disease progression or unacceptable toxicity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Forty-five patients were enrolled (23 pancreatic cancer, 10 colorectal, and the remaining 9 had other GI tumors); 42 patients received at least one dose of Minnelide. Grade\u2005\u2265\u20053 toxicities occurred in 69% of patients, most common neutropenia (38%). 2 patients with severe cerebellar toxicity who had a 2-fold higher triptolide concentration than other participants. ORR was 4%; the disease control rate (DCR) was 54% (15\/28). Choi criteria demonstrated a decrease in average tumor density in 57% (16\/28) patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This first-in-human, phase I clinical study identified a dose and schedule of Minnelide in patients with refractory GI cancers. The primary toxicity experienced was hematologic. Evidence of efficacy of Minnelide treatment in this group of patients was observed. The DCR ranged from ~2 to 6 months in 14\/28 (50%) of evaluable patients. Studies in monotherapy and combination treatments are underway.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad278","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T12:19:39Z","timestamp":1704284379000},"page":"132-141","source":"Crossref","is-referenced-by-count":31,"title":["First-in-Human Phase I Study of Minnelide in Patients With Advanced Gastrointestinal Cancers: Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity"],"prefix":"10.1093","volume":"29","author":[{"given":"Erkut","family":"Borazanci","sequence":"first","affiliation":[{"name":"HonorHealth Research Institute , Scottsdale, AZ , USA"},{"name":"Translational Genomics Research Institute (TGen) , Phoenix, AZ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Saluja","sequence":"additional","affiliation":[{"name":"Minneamrita , Tampa, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Gockerman","sequence":"additional","affiliation":[{"name":"Novella Clinical , Morrisville , NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohana","family":"Velagapudi","sequence":"additional","affiliation":[{"name":"Minneamrita , Tampa, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Korn","sequence":"additional","affiliation":[{"name":"HonorHealth Research Institute , Scottsdale, AZ , USA"},{"name":"Imaging Endpoints , Scottsdale, AZ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Von Hoff","sequence":"additional","affiliation":[{"name":"HonorHealth Research Institute , Scottsdale, AZ , USA"},{"name":"Translational Genomics Research Institute (TGen) , Phoenix, AZ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed","family":"Greeno","sequence":"additional","affiliation":[{"name":"Masonic Cancer Center , Minneapolis, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,3]]},"reference":[{"issue":"1","key":"2024020215170662600_CIT0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2024020215170662600_CIT0002","first-page":"327","article-title":"Triptolide and its derivatives as cancer therapies","volume-title":"Trends Pharmacol Sci","author":"Noel","year":"2019"},{"issue":"2","key":"2024020215170662600_CIT0003","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0304-3835(98)00222-5","article-title":"Antitumor activity of triptolide against cholangiocarcinoma growth in vitro and in hamsters","volume":"133","author":"Chawengkirttikul","year":"1998","journal-title":"Cancer Lett"},{"issue":"1","key":"2024020215170662600_CIT0004","first-page":"65","article-title":"Triptolide inhibits the growth and metastasis of solid tumors","volume":"2","author":"Yang","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"2024020215170662600_CIT0005","first-page":"9407","article-title":"Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70","volume-title":"Cancer Res","author":"Phillips","year":"2007"},{"key":"2024020215170662600_CIT0006","first-page":"630","article-title":"Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells","volume-title":"Blood","author":"Carter","year":"2006"},{"key":"2024020215170662600_CIT0007","first-page":"273","article-title":"Immunosuppressant PG490 (triptolide) induces apoptosis through the activation of caspase-3 and down-regulation of XIAP in U937 cells","volume-title":"Biochem Pharmacol","author":"Choi","year":"2003"},{"key":"2024020215170662600_CIT0008","first-page":"980","article-title":"Triptolide (PG-490) induces apoptosis of dendritic cells through sequential p38 MAP kinase phosphorylation and caspase 3 activation","volume-title":"Biochem Biophys Res Commun","author":"Liu","year":"2004"},{"issue":"5","key":"2024020215170662600_CIT0009","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00109-005-0022-4","article-title":"Mechanism of triptolide-induced apoptosis: effect on caspase activation and Bid cleavage and essentiality of the hydroxyl group of triptolide","volume":"84","author":"Wang","year":"2006","journal-title":"J Mol Med"},{"issue":"9","key":"2024020215170662600_CIT0010","doi-asserted-by":"crossref","first-page":"5243","DOI":"10.7314\/APJCP.2013.14.9.5243","article-title":"Synergism of cytotoxicity effects of triptolide and artesunate combination treatment in pancreatic cancer cell lines","volume":"14","author":"Liu","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"issue":"23","key":"2024020215170662600_CIT0011","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1038\/onc.2014.245","article-title":"GD3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer","volume":"34","author":"Sarkar","year":"2015","journal-title":"Oncogene"},{"issue":"3","key":"2024020215170662600_CIT0012","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.bbrc.2014.12.023","article-title":"Triptolide inhibits proliferation of Epstein-Barr virus-positive B lymphocytes by down-regulating expression of a viral protein LMP1","volume":"456","author":"Zhou","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"2024020215170662600_CIT0013","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3858\/emm.2012.44.11.072","article-title":"Triptolide inhibits ovarian cancer cell invasion by repression of matrix metalloproteinase 7 and 19 and upregulation of E-cadherin","volume":"44","author":"Zhao","year":"2012","journal-title":"Exp Mol Med"},{"issue":"10","key":"2024020215170662600_CIT0014","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1158\/1535-7163.MCT-09-0549","article-title":"Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA","volume":"8","author":"Visp\u00e9","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"2024020215170662600_CIT0015","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1158\/1078-0432.CCR-16-3275","article-title":"Re-engineering the Pancreas Tumor Microenvironment: A \u201cRegenerative Program\u201d Hacked","volume":"23","author":"Evan","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2024020215170662600_CIT0016","first-page":"Abstract nr CT165","article-title":"Phase II open label trial of Minnelide\u2122 in patients with chemotherapy refractory metastatic pancreatic cancer","author":"Propper","year":"2019"},{"issue":"2","key":"2024020215170662600_CIT0017","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1158\/1078-0432.CCR-15-1155","article-title":"Impaired synthesis of stromal components in response to Minnelide improves vascular function, drug delivery, and survival in pancreatic cancer","volume":"22","author":"Banerjee","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"156","key":"2024020215170662600_CIT0018","doi-asserted-by":"crossref","first-page":"156ra","DOI":"10.1126\/scitranslmed.3004334","article-title":"A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer","volume":"4","author":"Chugh","year":"2012  17","journal-title":"Sci Transl Med"},{"key":"2024020215170662600_CIT0019","first-page":"648","article-title":"Triptolide abrogates growth of colon cancer and induces cell cycle arrest by inhibiting transcriptional activation of E2F","volume-title":"Lab Invest","author":"Oliveira","year":"2015"},{"key":"2024020215170662600_CIT0020","first-page":"228","article-title":"New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1)","volume-title":"Eur J Cancer","author":"Eisenhauer","year":"2009"},{"key":"2024020215170662600_CIT0021","first-page":"1753","article-title":"Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria","volume-title":"J Clin Oncol","author":"Choi","year":"2007"},{"issue":"4","key":"2024020215170662600_CIT0022","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00234-017-1809-z","article-title":"Potentially reversible acute cerebellar toxicity associated with Minnelide","volume":"59","author":"Roshan","year":"2017","journal-title":"Neuroradiology"},{"key":"2024020215170662600_CIT0023","first-page":"e0171827","article-title":"Downregulation of Sp1 by Minnelide leads to decrease in HSP70 and decrease in tumor burden of gastric cancer","volume-title":"PLoS One","author":"Arora","year":"2017"},{"key":"2024020215170662600_CIT0024","first-page":"13","article-title":"Minnelide overcomes oxaliplatin resistance by downregulating the DNA repair pathway in pancreatic cancer","volume-title":"J Gastrointest Surg.","author":"Modi","year":"2016"},{"key":"2024020215170662600_CIT0025","first-page":"259","article-title":"Synergy of water soluble prodrug of triptolide (Minnelide) with gemcitabine and nab-paclitaxel in pancreatic cancer","volume-title":"J Clin Oncol","author":"Dudeja","year":"2016"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/2\/132\/56546066\/oyad278.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/2\/132\/56546066\/oyad278.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T15:18:02Z","timestamp":1706887082000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/2\/132\/7505299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,3]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,1,3]]},"published-print":{"date-parts":[[2024,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad278","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2,1]]},"published":{"date-parts":[[2024,1,3]]}}}